Nebulized Lidocaine in COVID-19, An Hypothesis
- PMID: 32505070
- PMCID: PMC7833589
- DOI: 10.1016/j.mehy.2020.109947
Nebulized Lidocaine in COVID-19, An Hypothesis
Abstract
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
Keywords: Anti-inflammatories; COVID-19; Cytokine-storm; Lidocaine; SARS-CoV-2.
Published by Elsevier Ltd.
References
-
- McKibbin W.J., Fernando R. The global macroeconomic impacts of Covid-19: seven scenarios. Ssrn Electron J. 2020;2020
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
